Frontiers | Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches Despite significant advancements in oncology, conventional chemotherapy remains the primary treatment for diverse malignancies. Acute kidney injury (AKI) sta...

🧬 Frontiers in Nephrology (doi.org/10.3389/fneph.2024.1436896) examines chemotherapy-related AKI.

Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI.

🔬 archbiopartners.com/our-science/cilastatin

#AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social

Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies Cisplatin is a highly effective chemotherapeutic agent that has been used for more than 50 years for a variety of cancers; however, its use is limited by toxicity, including nephrotoxicity. In this in...

A 2023 review (www.seminarsinnephrology.org/article/S027... shows how cisplatin causes AKI through inflammation, oxidative stress, and cell injury.

Learn more about the Phase II trial evaluating cilastatin to protect kidneys.

🔬 archbiopartners.com/our-science/cilastatin

#AKI #Cilastatin #NephSky

Cilastatin – Arch Biopartners

📉 Kidney Medicine @kidneymed.bsky.social (Dec 2024): Cilastatin was linked to a 74% lower AKI risk in clinical trials, 46% in observational studies. Overall: 48%.

Arch is supporting the PONTiAK Phase II trial, now recruiting.

🔬 archbiopartners.com/our-science/cilastatin

#Cilastatin #AKI #NephSky

Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023 - Scientific Reports Scientific Reports - Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023

🧬 2024 @springernature.com Scientific Reports study (nature.com/articles/s41598-024-67020-x) found DI-AKI from anticancer drugs has a ~23.6% fatality rate, rising sharply after 2010. Cilastatin is in a Phase II trial for DI-AKI.
🔬 archbiopartners.com/our-science/cilastatin
#AKI #Cilastatin #NephSky

Frontiers | Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors Introduction: Acute Kidney Injury (AKI) is a common clinical syndrome. Drug-Induced Acute Kidney Injury (DI-AKI) is associated with exposure to nephrotoxic m...

Frontiers cohort study (doi.org/10.3389/fmed.2024.1459170), part of a research topic, maps hospital drug classes linked to drug-induced acute kidney injury (DI-AKI).

PONTIAK Phase II trial of cilastatin to prevent DI-AKI now recruiting.

🔬 archbiopartners.com/cilastatin

#AKI #Cilastatin #NephSky

Frontiers | High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights High-dose methotrexate (HD-MTX) toxicity represents a significant clinical challenge in oncology, commonly resulting in acute kidney injury (AKI), myelosuppr...

March 2025 Frontiers in Medicine case series (doi.org/10.3389/fmed.2025.1495705), part of a research topic, reports dialysis rescue after methotrexate-induced AKI.
Arch is supporting a Phase II trial of cilastatin for kidney protection.

🔬 archbiopartners.com/cilastatin
#AKI #Cilastatin #KidneyCare

Arch Biopartners Company Logo, and stock tickers (ARCH: TSX.V, and ACHFF: OTCQB). Headline, July 22, 2025 Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials:

🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment
🔹 LSALT peptide: cardiac surgery-associated AKI

🔗 archbiopartners.com/investor-hub...

#AKI #Cilastatin #LSALTpeptide #ArchNews

Frontiers | Drug-induced acute kidney injury: a cohort study on incidence, identification of pathophysiological mechanisms, and prognostic factors Introduction: Acute Kidney Injury (AKI) is a common clinical syndrome. Drug-Induced Acute Kidney Injury (DI-AKI) is associated with exposure to nephrotoxic m...

💊 2024 study in “Frontiers in Medicine” (doi.org/10.3389/fmed.2024.1459170): in a series about drug-induced AKI (DI-AKI), found the problem remains a top cause of hospital AKI.

Arch is advancing cilastatin to help prevent this risk.

🔬 archbiopartners.com/cilastatin

#Cilastatin #AKI #KidneyCare

Cilastatin – Arch Biopartners

💊 2023 Kidney Int. Reports study (doi.org/10.1016/j.ekir.2023.07.037) finds drug-induced AKI (DI-AKI) patients are more likely to develop Stage 3 AKI and kidney disease at discharge.
Arch is developing cilastatin to help prevent DI-AKI - archbiopartners.com/cilastatin
#AKI #Cilastatin #KidneyCare

Cilastatin – Arch Biopartners

As part of a new series revisiting key research, Arch is highlighting a 2018 JCI study (doi.org/10.1172/JCI96640) showing how Cilastatin blocks DPEP1-driven contrast uptake and protects kidney function in AKI models.
📖 archbiopartners.com/our-science/cilastatin/
#Cilastatin #DPEP1 #ArchScience

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience....

📘 A new review in eClinicalMedicine (The Lancet) shows how ADDIKD guidelines are reducing AKI risk from anticancer drugs.

Reflects growing interest in kidney-protective approaches—including those under study with Cilastatin.

📖 dub.sh/addikd-04-2025

#ArchBiopartners #AKI #Cilastatin #KidneyCare

Our Science – Arch Biopartners

Arch Biopartners is advancing two lead drug candidates:

🧪 LSALT peptide: targets inflammation-related AKI
🔬 Cilastatin: repurposed to prevent toxin-related AKI

Learn more: archbiopartners.com/our-science

#ArchBiopartners #AKI #LSALTpeptide #Cilastatin #ArchScience

Parenteral Antibiotics & Respiratory Meds: Brands & Dosages
#Montika #Salmeterol #Seretide #Fluticasone #Salmicort #Beclomethasone #Bekson #Ventide #Piperacillin #Tazobactam #Tanzo #Tazocin #Teicoplanin #Targocid #Imipenem #Cilastatin #Tienam #Meropenem